$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs

$ohcs Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023065030 Filed on August 09, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$453.7K	$322.4K	$344.2K
YoY Change	30.69%	-6.32%	19.18%
Cost Of Revenue	$79.75K	$59.16K	$68.68K
YoY Change	22.65%	-13.86%	0.06%
Gross Profit	$374.0K	$263.3K	$275.5K
YoY Change	32.55%	-4.44%	25.14%
Gross Profit Margin	82.42%	81.65%	80.05%
Selling, General & Admin	$1.720M	$2.690M	$2.747M
YoY Change	-35.13%	-2.07%	39.26%
% of Gross Profit	459.93%	1021.99%	997.24%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$7.774K	$3.502K	$202.4K
YoY Change	-498.67%	-98.27%
% of Gross Profit	2.08%	1.33%	73.46%
Operating Expenses	$1.720M	$2.690M	$2.747M
YoY Change	-35.12%	-2.07%	94.21%
Operating Profit	-$1.346M	-$2.427M	-$2.472M
YoY Change	-43.18%	-1.8%	106.94%
Interest Expense	$144.5K	$114.8K	$68.17K
YoY Change	38.55%	68.41%	219.35%
% of Operating Profit
Other Income/Expense, Net	-$431.8K	-$431.2K	-$428.6K
YoY Change	-40.11%	0.59%	230.13%
Pretax Income	-$1.778M	-$2.858M	-$2.900M
YoY Change	-42.46%	-1.45%	67.82%
Income Tax		$2.025K	$889.6K
% Of Pretax Income
Net Earnings	-$1.778M	-$2.860M	-$3.790M
YoY Change	-42.46%	-24.53%	186.19%
Net Earnings / Revenue	-391.9%	-887.18%	-1101.24%
Basic Earnings Per Share	-$0.04	-$0.07	-$0.10
Diluted Earnings Per Share	-$0.04	-$0.07	-$0.10
COMMON SHARES
Basic Shares Outstanding	39.97M shares	40.22M shares	38.97M shares
Diluted Shares Outstanding	39.97M shares	40.12M shares	38.97M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$340.0K	$319.5K	$1.654M
YoY Change	-68.45%	-80.68%
Cash & Equivalents	$200.4K	$197.1K	$1.212M
Short-Term Investments	$130.0K	$122.4K	$442.3K
Other Short-Term Assets
YoY Change
Inventory	$6.979K
Prepaid Expenses
Receivables	$570.0K	$426.5K	$609.7K
Other Receivables	$200.0K	$200.0K	$0.00
Total Short-Term Assets	$1.114M	$946.0K	$2.264M
YoY Change	-33.72%	-58.21%
LONG-TERM ASSETS
Property, Plant & Equipment	$80.35K	$69.08K	$9.572K
YoY Change	165.01%	621.71%
Goodwill	$815.5K	$815.5K	$3.636M
YoY Change	-77.57%	-77.57%
Intangibles	$2.000K	$2.250K	$1.700M
YoY Change	-99.88%	-99.87%
Long-Term Investments
YoY Change
Other Assets			$0.00
YoY Change
Total Long-Term Assets	$1.236M	$1.193M	$5.717M
YoY Change	-78.42%	-79.14%
TOTAL ASSETS
Total Short-Term Assets	$1.114M	$946.0K	$2.264M
Total Long-Term Assets	$1.236M	$1.193M	$5.717M
Total Assets	$2.350M	$2.139M	$7.981M
YoY Change	-68.27%	-73.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.080M	$1.113M	$1.561M
YoY Change	-31.95%	-28.66%
Accrued Expenses	$667.4K	$545.1K	$63.43K
YoY Change	923.33%	759.42%
Deferred Revenue
YoY Change
Short-Term Debt	$1.790M	$1.088M	$169.8K
YoY Change	1155.0%	540.49%
Long-Term Debt Due	$3.630M	$3.338M	$5.300K
YoY Change	68390.57%	62888.68%
Total Short-Term Liabilities	$7.258M	$6.154M	$1.799M
YoY Change	303.04%	242.05%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$4.080K	$2.187M
YoY Change	-100.0%	-99.81%
Other Long-Term Liabilities	$2.839K	$4.083K	$317.6K
YoY Change	-99.06%	-98.71%
Total Long-Term Liabilities	$2.839K	$4.083K	$2.504M
YoY Change	-99.9%	-99.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.258M	$6.154M	$1.799M
Total Long-Term Liabilities	$2.839K	$4.083K	$2.504M
Total Liabilities	$7.513M	$6.406M	$4.304M
YoY Change	64.11%	48.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$26.62M	-$24.85M	-$15.74M
YoY Change	41.38%	57.84%
Common Stock	$39.97K	$39.97K	$38.98K
YoY Change	-0.79%	2.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.161M	-$4.266M	$3.678M
YoY Change
Total Liabilities & Shareholders Equity	$2.350M	$2.139M	$7.981M
YoY Change	-68.27%	-73.2%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$1.778M	-$2.860M	-$3.790M
YoY Change	-42.46%	-24.53%	186.19%
Depreciation, Depletion And Amortization	$7.774K	$3.502K	$202.4K
YoY Change	-498.67%	-98.27%
Cash From Operating Activities	-$880.0K	-$1.038M	-$42.46K
YoY Change	-0.01%	2345.78%
INVESTING ACTIVITIES
Capital Expenditures	$20.00K	$19.55K	-$2.440K
YoY Change	-191.41%	-901.23%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$222.7K	$1.777M
YoY Change		-87.47%
Cash From Investing Activities	-$10.00K	$203.2K	$1.774M
YoY Change	-54.3%	-88.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	900.0K	810.8K	-956.8K
YoY Change	142.48%	-184.74%
NET CHANGE
Cash From Operating Activities	-880.0K	-1.038M	-42.46K
Cash From Investing Activities	-10.00K	203.2K	1.774M
Cash From Financing Activities	900.0K	810.8K	-956.8K
Net Change In Cash	10.00K	-24.55K	775.1K
YoY Change	-101.88%	-103.17%
FREE CASH FLOW
Cash From Operating Activities	-$880.0K	-$1.038M	-$42.46K
Capital Expenditures	$20.00K	$19.55K	-$2.440K
Free Cash Flow	-$900.0K	-$1.058M	-$40.02K
YoY Change	4.87%	2543.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41210
	dei	Entity Registrant Name EntityRegistrantName	OPTIMUS HEALTHCARE SERVICES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	65-0181535
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1400 Old Country Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 306
	dei	Entity Address City Or Town EntityAddressCityOrTown	Westbury
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11590
	dei	City Area Code CityAreaCode	(516)
	dei	Local Phone Number LocalPhoneNumber	806-4201
	dei	Security12b Title Security12bTitle	None
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39967598	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	197121	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	751017	usd
CY2023Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	426455	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	525064	usd
CY2023Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	200000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	200689	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	122401	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	104877	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	144199	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	945977	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1725846	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	305818	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	339614	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	69082	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56196	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2250	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2750	usd
CY2023Q2	us-gaap	Goodwill Goodwill	815500	usd
CY2022Q4	us-gaap	Goodwill Goodwill	815500	usd
CY2023Q2	us-gaap	Assets Assets	2138627	usd
CY2022Q4	us-gaap	Assets Assets	2939906	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1113438	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	738395	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	545127	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	581802	usd
CY2023Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	137746	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	140060	usd
CY2023Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	950000	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	200	usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3333096	usd
CY2023Q2	us-gaap	Loans Payable Current LoansPayableCurrent	5304	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	5304	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	69738	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	67052	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6154449	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1532813	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	247825	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283092	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	2759961	usd
CY2023Q2	us-gaap	Program Rights Obligations Noncurrent ProgramRightsObligationsNoncurrent	4083	usd
CY2022Q4	us-gaap	Program Rights Obligations Noncurrent ProgramRightsObligationsNoncurrent	6562	usd
CY2023Q2	us-gaap	Liabilities Liabilities	6406357	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4582428	usd
CY2023Q2	ohcs	Preferred Stock Value1 PreferredStockValue1	2	usd
CY2022Q4	ohcs	Preferred Stock Value1 PreferredStockValue1	2	usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	8106	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	8106	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39967598	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39967598	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38286598	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38286598	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	39968	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	38287	usd
CY2022Q4	us-gaap	Preferred Stock Shares Subscribed But Unissued Value PreferredStockSharesSubscribedButUnissuedValue	1206	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20532830	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17343671	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24846510	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19032561	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-4265604	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1641289	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	-2126	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-1233	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4267730	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1642522	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2138627	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2939906	usd
CY2023Q2	us-gaap	Revenues Revenues	322414	usd
CY2022Q2	us-gaap	Revenues Revenues	344157	usd
	us-gaap	Revenues Revenues	594056	usd
	us-gaap	Revenues Revenues	653786	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	59158	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	68676	usd
	us-gaap	Cost Of Revenue CostOfRevenue	139182	usd
	us-gaap	Cost Of Revenue CostOfRevenue	136853	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	263256	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	275481	usd
	us-gaap	Gross Profit GrossProfit	454874	usd
	us-gaap	Gross Profit GrossProfit	516933	usd
CY2023Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1183518	usd
CY2022Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1405192	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2601461	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3886702	usd
CY2023Q2	ohcs	Personnel Expenses PersonnelExpenses	844196	usd
CY2022Q2	ohcs	Personnel Expenses PersonnelExpenses	584775	usd
	ohcs	Personnel Expenses PersonnelExpenses	1730452	usd
	ohcs	Personnel Expenses PersonnelExpenses	1042311	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	600536	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	585550	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1027089	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1233000	usd
CY2023Q2	us-gaap	Professional Fees ProfessionalFees	62200	usd
CY2022Q2	us-gaap	Professional Fees ProfessionalFees	171684	usd
	us-gaap	Professional Fees ProfessionalFees	203479	usd
	us-gaap	Professional Fees ProfessionalFees	358151	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	2690450	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2747201	usd
	us-gaap	Operating Expenses OperatingExpenses	5562481	usd
	us-gaap	Operating Expenses OperatingExpenses	6520164	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2427194	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2471720	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5107607	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6003231	usd
CY2023Q2	ohcs	Amortization Of Financing Cost AmortizationOfFinancingCost	288151	usd
CY2022Q2	ohcs	Amortization Of Financing Cost AmortizationOfFinancingCost	277761	usd
	ohcs	Amortization Of Financing Cost AmortizationOfFinancingCost	573136	usd
	ohcs	Amortization Of Financing Cost AmortizationOfFinancingCost	548993	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	114796	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	68165	usd
	us-gaap	Interest Expense InterestExpense	218584	usd
	us-gaap	Interest Expense InterestExpense	118724	usd
CY2023Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-32211	usd
CY2022Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-82714	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	78510	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-96479	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-431158	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-428640	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-705210	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-764196	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2858352	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2900360	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5812817	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6767427	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2025	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	889625	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2025	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	666616	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-2860377	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-3789985	usd
	us-gaap	Profit Loss ProfitLoss	-5814842	usd
	us-gaap	Profit Loss ProfitLoss	-7434043	usd
CY2023Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-474	usd
CY2022Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	51	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-893	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	7	usd
CY2023Q2	ohcs	Net Income Loss Available To Common Stockholder Basic1 NetIncomeLossAvailableToCommonStockholderBasic1	-2859903	usd
CY2022Q2	ohcs	Net Income Loss Available To Common Stockholder Basic1 NetIncomeLossAvailableToCommonStockholderBasic1	-3790036	usd
	ohcs	Net Income Loss Available To Common Stockholder Basic1 NetIncomeLossAvailableToCommonStockholderBasic1	-5813949	usd
	ohcs	Net Income Loss Available To Common Stockholder Basic1 NetIncomeLossAvailableToCommonStockholderBasic1	-7434050	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2860377	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3789985	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5814842	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7434043	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.1
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.2
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40116769	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38974598	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39967476	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37538640	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1642522	usd
CY2023Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	725000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	206755	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1211188	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2954465	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2454044	usd
CY2023Q2	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-136827	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	188795	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	994723	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2860377	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4267730	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5412484	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	467500	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2481510	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3644058	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4717436	usd
CY2022Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	375000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	111847	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	857835	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1405193	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3789985	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3677326	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5814842	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7434043	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7166	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	202716	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2601461	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3886703	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	78510	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-96479	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	573136	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	548993	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1215	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2303	usd
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	666616	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-99298	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	135033	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	17524	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	345	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	375043	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	8010	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-36675	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5023	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2290232	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2152578	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-9000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	936330	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2203666	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	713622	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1403666	usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	19552	usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	7496	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	203156	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	801504	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	725000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	375000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	136827	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1935000	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	949800	usd
	us-gaap	Payments For Proceeds From Deposit On Loan PaymentsForProceedsFromDepositOnLoan	2479	usd
	us-gaap	Payments For Proceeds From Deposit On Loan PaymentsForProceedsFromDepositOnLoan	2045	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	2314	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	6068	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1533180	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2301887	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-553896	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	950813	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	751017	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	260838	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	197121	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1211651	usd
	us-gaap	Interest Paid Net InterestPaidNet	200700	usd
	us-gaap	Interest Paid Net InterestPaidNet	99000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	ohcs	Common Stock Issued For Business Combination CommonStockIssuedForBusinessCombination	0	usd
	ohcs	Common Stock Issued For Business Combination CommonStockIssuedForBusinessCombination	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. Nature of operations</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Optimus Healthcare Services, Inc. (formerly Between Dandelions, Inc., “Optimus”, “Company”) was initially organized under the laws of Florida on February 26, 1990, as Phoenix Management Associates, Inc. Over the ensuing years, the Company made a series of amendments to its Articles of Incorporation relating to authorization of various series of Preferred Shares and made a series of name changes. The current name of Optimus Healthcare Services, Inc. became effective with the State of Florida on January 24, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is dedicated to: (1) advancing access to clinical trial research; and (2) improving and simplifying access to vaccines and pharmaceutical products. Currently the Company provides these services through its portfolio companies, Clinical Research Alliance, Inc. (CRA), and Worker’s Health Rx (d/b/a Vitality Rx).</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of equity issued for services, valuation of equity associated with convertible debt, the valuation of derivative liabilities, and the valuation of deferred tax assets. Actual results could differ from these estimates.</p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><span style="text-decoration:underline">Reclassification</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts included in prior year financial statements have been reclassified to conform to the current year presentation. These reclassifications did not have a material impact on the Company’s previously reported financial statements.</p>
	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt"><span style="text-decoration:underline">Revenue Recognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify">The Company recognizes revenue in accordance with Accounting Standards Update (“ASU”) 2014-09, “<i>Revenue from contracts with customers,”</i> (Topic 606). Revenue is recognized when a customer obtains control of promised goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify">The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. The Company’s main revenue stream is from services. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon delivery. For services performed by CRA, the Company’s performance obligations are generally met at the point in time the services are rendered.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><span style="text-decoration:underline">Concentration of Credit Risk</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in certificates of deposit, deposit accounts or treasury bills. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity.</p>
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	197121	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	751017	usd
	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	0	usd
CY2022	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	363153	usd
CY2022	ohcs	Accounts Receivable Percentage AccountsReceivablePercentage	0.10	pure
	ohcs	Annual Revenue Percentage AnnualRevenuePercentage	0.10	pure
CY2022Q2	ohcs	Annual Revenue Percentage AnnualRevenuePercentage	0.10	pure
	ohcs	Annual Revenue Percentage AnnualRevenuePercentage	0.10	pure
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1183518	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1405192	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	188795	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2601461	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3886702	usd
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	395550	shares
CY2022Q2	us-gaap	Advertising Expense AdvertisingExpense	7400	usd
	us-gaap	Advertising Expense AdvertisingExpense	17150	usd
	ohcs	Lease Agreement Commencing Description LeaseAgreementCommencingDescription	The Company entered into a lease agreement commencing on February 1, 2021 through August 31, 2026, for 1,246 square feet of office space located at One Dupont Street, Suite 112, Plainview, New York, 11803.
	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	179	usd
	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.50	pure
	ohcs	Warrants Warrants	1705000	shares
	ohcs	Warrants Warrants	1705000	shares
	ohcs	Stock Options StockOptions	2078750	shares
	ohcs	Stock Options StockOptions	987500	shares
	ohcs	Convertible Notes Payable Shares ConvertibleNotesPayableShares	4400000	shares
	ohcs	Convertible Notes Payable Shares ConvertibleNotesPayableShares	4400000	shares
	us-gaap	Auction Market Preferred Securities Shares Issued AuctionMarketPreferredSecuritiesSharesIssued	406664	shares
	us-gaap	Auction Market Preferred Securities Shares Issued AuctionMarketPreferredSecuritiesSharesIssued	406664	shares
	ohcs	Totalshares Totalshares	8590414	shares
	ohcs	Totalshares Totalshares	7499164	shares
CY2023Q2	ohcs	Office Lease OfficeLease	456819	usd
CY2022Q4	ohcs	Office Lease OfficeLease	456819	usd
CY2023Q2	ohcs	Equipment Lease EquipmentLease	5611	usd
CY2022Q4	ohcs	Equipment Lease EquipmentLease	2063	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	156612	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	119268	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	305818	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	339614	usd
CY2023Q2	ohcs	Office Lease Liability OfficeLeaseLiability	316513	usd
CY2022Q4	ohcs	Office Lease Liability OfficeLeaseLiability	348081	usd
CY2023Q2	ohcs	Equipment Lease Liability EquipmentLeaseLiability	1050	usd
CY2022Q4	ohcs	Equipment Lease Liability EquipmentLeaseLiability	2063	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	69738	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	67052	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	247825	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283092	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	45849	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	91335	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	93837	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive	88269	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive	49677	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	368967	usd
CY2023Q2	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	51404	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	317563	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	197121	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	751017	usd
CY2023Q2	us-gaap	Capital Units Net Amount CapitalUnitsNetAmount	5208472	usd
CY2022Q4	us-gaap	Capital Units Net Amount CapitalUnitsNetAmount	193033	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	5814842	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	7434043	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	2860377	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	3789985	usd
CY2023Q2	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	24846510	usd
CY2022Q4	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	19032561	usd
	ohcs	Going Concern Term GoingConcernTerm	P1Y
	us-gaap	Principal Transactions Revenue PrincipalTransactionsRevenue	2200000	usd
CY2023Q2	us-gaap	Investment Maturity Date InvestmentMaturityDate	2024-05-25
CY2023Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	950000	usd
CY2020Q4	ohcs	Business Acquisition Percentage Of Voting Interest Acquired BusinessAcquisitionPercentageOfVotingInterestAcquired	0.73	pure
CY2020Q4	ohcs	Business Acquisition Percentage Of Voting Interest Acquired BusinessAcquisitionPercentageOfVotingInterestAcquired	0.51	pure
CY2021Q3	us-gaap	Memberships In Exchanges Owned MembershipsInExchangesOwned	425000	usd
CY2021Q3	us-gaap	Shares Issued SharesIssued	425000	shares
	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	1
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	1.25
	us-gaap	Goodwill Translation And Purchase Accounting Adjustments GoodwillTranslationAndPurchaseAccountingAdjustments	815500	usd
CY2022Q4	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	2000000	shares
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	400000	shares
CY2022Q4	us-gaap	Loans Payable LoansPayable	200000	usd
CY2022Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	100000	usd
CY2022Q4	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	3600000	usd
CY2022Q4	us-gaap	Beneficial Interest BeneficialInterest	100000	usd
CY2022Q4	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	3500000	usd
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	3627927	usd
CY2022Q4	us-gaap	Gain Loss On Sale Of Property GainLossOnSaleOfProperty	127927	usd
CY2023Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	200000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	200689	usd
CY2023Q2	ohcs	Aggregate Principal Amount AggregatePrincipalAmount	200000	usd
CY2023Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	76249	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	56696	usd
CY2023Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	23896	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	23896	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	100145	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	80592	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	31063	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24396	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	69082	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56196	usd
CY2023Q2	us-gaap	Depreciation Depreciation	3502	usd
	us-gaap	Depreciation Depreciation	6666	usd
CY2022Q2	us-gaap	Depreciation Depreciation	390	usd
	us-gaap	Depreciation Depreciation	690	usd
CY2023Q2	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	250000	usd
	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.0164	pure
	us-gaap	Line Of Credit Facility Periodic Payment LineOfCreditFacilityPeriodicPayment	2314	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	750	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	250	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2250	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2750	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	250	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	102874	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	202026	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	327440	usd
CY2022	ohcs	Gross Unrealized Loss GrossUnrealizedLoss	-183241	usd
CY2022	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment	144199	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	78510	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-96479	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	161269	usd
	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	82759	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	144081	usd
	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	47602	usd
CY2023Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	137746	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	140060	usd
CY2023Q2	ohcs	Notes Payable Related Parties Classified As Current NotesPayableRelatedPartiesClassifiedAsCurrent	950000	usd
CY2022Q4	ohcs	Notes Payable Related Parties Classified As Current NotesPayableRelatedPartiesClassifiedAsCurrent	200	usd
CY2023Q2	ohcs	Issued3 Issued3	10100	usd
CY2022Q4	ohcs	No Coupon Due On Demand Issued Three NoCouponDueOnDemandIssuedThree	200	usd
	us-gaap	Stock Issued1 StockIssued1	950000	usd
	ohcs	Coupon Coupon	0.12	pure
CY2023Q2	ohcs	Coupon Due On Demand Issued Two CouponDueOnDemandIssuedTwo	950000	usd
	ohcs	Longterm Notes Payable Related Party LongtermNotesPayableRelatedParty	950000	usd
CY2022	ohcs	Longterm Notes Payable Related Party LongtermNotesPayableRelatedParty	200	usd
CY2022Q3	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	362000	shares
CY2022Q3	us-gaap	Other Notes Payable OtherNotesPayable	25000	usd
CY2022Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	296839	usd
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	218238	usd
CY2023Q2	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	950000	usd
CY2023Q2	us-gaap	Investment Interest Rate InvestmentInterestRate	0.12	pure
CY2020Q2	us-gaap	Loans Receivable With Fixed Rates Of Interest1 LoansReceivableWithFixedRatesOfInterest1	145683	usd
CY2021Q1	us-gaap	Loans Receivable With Fixed Rates Of Interest1 LoansReceivableWithFixedRatesOfInterest1	148975	usd
CY2023Q2	us-gaap	Grants Receivable Current GrantsReceivableCurrent	126546	usd
CY2020Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	126546	usd
	us-gaap	Loans Receivable Description Of Variable Rate Basis LoansReceivableDescriptionOfVariableRateBasis	The unforgiven portion of the PPP loan totaling $19,137 is payable over five years at an interest rate of 1%, with a deferral of payments for the first twelve months.
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4083	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5304	usd
CY2021Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	148975	usd
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	3333096	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2759961	usd
CY2023Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	0	usd
CY2023Q2	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	3333096	usd
CY2021Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2200000	usd
CY2021Q2	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	2200000	usd
CY2021Q2	ohcs	Aggregate Purchase Price AggregatePurchasePrice	2000000	usd
CY2021Q2	ohcs	Shares Of Common Stock SharesOfCommonStock	165000	shares
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1
CY2021Q2	ohcs	Ownership Percentage OwnershipPercentage	0.0999	pure
CY2021Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.10	pure
CY2023Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	1.25
CY2023Q2	ohcs	Equity Method Investments Ownership Percentages EquityMethodInvestmentsOwnershipPercentages	0.0999	pure
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2200000	usd
CY2022Q2	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	2200000	usd
CY2022Q2	ohcs	Aggregate Purchase Price AggregatePurchasePrice	2000000	usd
CY2022Q2	ohcs	Shares Of Common Stock SharesOfCommonStock	1540000	shares
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1
CY2022Q2	ohcs	Equity Method Investments Ownership Percentages EquityMethodInvestmentsOwnershipPercentages	0.0999	pure
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	114796	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	218584	usd
CY2022Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	68165	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	118724	usd
CY2023Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	288151	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	573136	usd
CY2022Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	277761	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	548993	usd
CY2021Q3	us-gaap	Demutualization By Insurance Entity Securities Issued Quantity Of Shares DemutualizationByInsuranceEntitySecuritiesIssuedQuantityOfShares	2000000	shares
CY2021Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	1
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4141000	shares
CY2022	ohcs	Raised Pursuant Amount RaisedPursuantAmount	1956000	usd
	ohcs	Raised Pursuant Amount RaisedPursuantAmount	725000	usd
CY2020Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	9998899	shares
CY2020Q4	ohcs	Cancelled Shares CancelledShares	9998889	shares
CY2023Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	250000	shares
CY2023Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	136827	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	250000	shares
	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	1.39
	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.25	pure
	us-gaap	Restricted Stock Expense RestrictedStockExpense	395550	usd
CY2023Q2	us-gaap	Share Price SharePrice	1.35
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1.39
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.3213	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0402	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M3D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5895000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.69
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y1M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	250000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.39
	ohcs	Weighted Average Remaining Term Options Granted WeightedAverageRemainingTermOptionsGranted	P10Y
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6145000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.68
	ohcs	Weighted Average Remaining Term Options Outstanding At Ending Balance WeightedAverageRemainingTermOptionsOutstandingAtEndingBalance	P8Y8M8D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2078750	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.72
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M23D
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2601461	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3886702	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4500861	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	2000000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	65000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	2065000	shares
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	3042200	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1705000	shares
	ohcs	Weighted Average Average Exercise Price Beginning Balance WeightedAverageAverageExercisePriceBeginningBalance	1.25
	ohcs	Weighted Average Remaining Term Beginning Balance WeightedAverageRemainingTermBeginningBalance	P4Y4M2D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1705000	shares
	ohcs	Weighted Average Average Exercise Price Ending Balance WeightedAverageAverageExercisePriceEndingBalance	1.25
	ohcs	Weighted Average Remaining Term Ending Balance1 WeightedAverageRemainingTermEndingBalance1	P3Y10M2D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1705000	shares
	ohcs	Weighted Average Average Exercise Price Warrants Exercisable WeightedAverageAverageExercisePriceWarrantsExercisable	1.25
	ohcs	Weighted Average Remaining Term Warrants Exercisable1 WeightedAverageRemainingTermWarrantsExercisable1	P3Y10M2D
	ohcs	Related Party Loan Amount RelatedPartyLoanAmount	450000	usd
	srt	Demand Deposit Liabilities Interest Bearing Average Rate Paid DemandDepositLiabilitiesInterestBearingAverageRatePaid	0.12	pure
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2023Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Preferred Stock Shares Subscribed But Unissued Value PreferredStockSharesSubscribedButUnissuedValue		usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38974598	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39967476	shares
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit		usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable		usd
CY2023Q2	us-gaap	Advertising Expense AdvertisingExpense		usd
	us-gaap	Advertising Expense AdvertisingExpense		usd
CY2023Q2	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent		usd
	ohcs	Gross Unrealized Loss GrossUnrealizedLoss		usd
	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment		usd
CY2023Q2	ohcs	No Coupon Due On Demand Issued Three NoCouponDueOnDemandIssuedThree		usd
CY2022Q4	ohcs	Coupon Due On Demand Issued Two CouponDueOnDemandIssuedTwo		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	ohcs	Weighted Average Remaining Term Options Exercised WeightedAverageRemainingTermOptionsExercised
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	ohcs	Weighted Average Remaining Term Options Cancelled WeightedAverageRemainingTermOptionsCancelled
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod		shares
	ohcs	Weighted Average Exercise Price Issued WeightedAverageExercisePriceIssued
	ohcs	Weighted Average Remaining Term Issued WeightedAverageRemainingTermIssued
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	ohcs	Weighted Average Average Exercise Price Exercised WeightedAverageAverageExercisePriceExercised
	ohcs	Weighted Average Remaining Term Exercised WeightedAverageRemainingTermExercised
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	ohcs	Weighted Average Average Exercise Price Expired WeightedAverageAverageExercisePriceExpired
	ohcs	Weighted Average Remaining Term Expired WeightedAverageRemainingTermExpired
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001892025

Files In Submission

Name	View Source	Status
0001213900-23-065030-index-headers.html	Edgar Link	pending
0001213900-23-065030-index.html	Edgar Link	pending
0001213900-23-065030.txt	Edgar Link	pending
0001213900-23-065030-xbrl.zip	Edgar Link	pending
f10q0623ex10-1_optimushealth.htm	Edgar Link	pending
f10q0623ex31-1_optimushealth.htm	Edgar Link	pending
f10q0623ex31-2_optimushealth.htm	Edgar Link	pending
f10q0623ex32-1_optimushealth.htm	Edgar Link	pending
f10q0623ex32-2_optimushealth.htm	Edgar Link	pending
f10q0623_optimushealth.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ohcs-20230630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
ohcs-20230630_cal.xml	Edgar Link	unprocessable
ohcs-20230630_def.xml	Edgar Link	unprocessable
ohcs-20230630_lab.xml	Edgar Link	unprocessable
ohcs-20230630_pre.xml	Edgar Link	unprocessable
f10q0623_optimushealth_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs

2023 Q3 Form 10-Q Financial Statement

#000121390023065030 Filed on August 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OHCS Optimus Healthcare Services, Inc. Stock $ohcs

2023 Q3 Form 10-Q Financial Statement

#000121390023065030 Filed on August 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs